XOMA Royalty (NASDAQ:XOMA) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of XOMA Royalty (NASDAQ:XOMA) from a hold rating to a buy rating in a research note published on Saturday.

Several other brokerages have also recently weighed in on XOMA. Benchmark began coverage on shares of XOMA Royalty in a research report on Thursday, April 17th. They set a “buy” rating and a $35.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $104.00 price target on shares of XOMA Royalty in a research report on Wednesday, May 28th.

XOMA Royalty Price Performance

Shares of XOMA Royalty stock opened at $25.83 on Friday. XOMA Royalty has a 52-week low of $18.35 and a 52-week high of $35.00. The stock has a market capitalization of $309.11 million, a price-to-earnings ratio of -22.46 and a beta of 0.93. The company has a fifty day moving average of $25.73 and a 200-day moving average of $24.23. The company has a debt-to-equity ratio of 1.18, a quick ratio of 5.54 and a current ratio of 5.54.

XOMA Royalty (NASDAQ:XOMA) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.32. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. The company had revenue of $15.91 million during the quarter, compared to analysts’ expectations of $6.75 million. Equities research analysts expect that XOMA Royalty will post -1.41 EPS for the current year.

Insider Buying and Selling at XOMA Royalty

In other XOMA Royalty news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the completion of the sale, the insider owned 1,267,545 shares of the company’s stock, valued at $34,350,469.50. This represents a 23.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Owen Hughes sold 25,637 shares of the stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total transaction of $650,667.06. Following the sale, the chief executive officer directly owned 62,701 shares of the company’s stock, valued at $1,591,351.38. The trade was a 29.02% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.10% of the company’s stock.

Institutional Investors Weigh In On XOMA Royalty

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in shares of XOMA Royalty by 1,063.8% in the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,585 shares during the period. Nuveen Asset Management LLC lifted its position in shares of XOMA Royalty by 3.8% in the 4th quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 527 shares during the period. Northern Trust Corp lifted its position in shares of XOMA Royalty by 1.5% in the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock worth $2,396,000 after purchasing an additional 1,340 shares during the period. Bank of America Corp DE lifted its position in shares of XOMA Royalty by 34.7% in the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 2,009 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of XOMA Royalty by 89.8% in the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 7,619 shares during the period. 95.92% of the stock is owned by hedge funds and other institutional investors.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.